Norway· NO-ID_86CB34FF-FF12-4A4F-A3F4-A87217259702

Rxulti

A brexpiprazole product containing brexpiprazole, registered in Norway by Abacus Medicine A/S. The same ATC class is registered in 12 of our 19 countries.

ATC N05AX16

Checked against FEST (Norway) on

Informational only — not a medical device.

SOURCE REGISTER · NOFEST (Norway)normalisedRxultiATCN05AX16REGISTER NO.NO-ID_86CB34FF-FF12-4…PACKS LISTED3CHECKEDSeptember 25, 2026

Where it is registered

Brexpiprazole is registered in 12 of 19 countries.

Countries holding a registration under ATC N05AX16 (brexpiprazole), each read from that country’s own register.

  • This record: Norway, from FEST (Norway)
  • 8 of them publish a price we can compare per daily dose

Brexpiprazole · ATC N05AX16

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of brexpiprazole costs, country by country.

Normalised to the WHO defined daily dose (3 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Brexpiprazole · price per daily dose (3 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$8.31
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FEST (Norway)
Active substance
Brexpiprazole
Manufacturer
Abacus Medicine A/S
Country
Norway (NO)
ATC code
N05AX16
ATC class
Brexpiprazole
Defined daily dose
3 mg, O
Reimbursed
Not published by this register
Source register
FEST (Norway)
Last checked
September 25, 2026

Packs & prices · 3

1 priced
  • no_merkevare_id
    ID_86CB34FF-FF12-4A4F-A3F4-A87217259702
  • no_varenummer
    445264
    28
    NOK 924.9
  • gtin
    5712440026278

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

209 interactions on record for brexpiprazole.

Graded by severity as the source publishes them — 52 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Brexpiprazole · interactions on record

209 records

  • 52 severe
  • 157 moderate

Most severe, free to view

  • ClotrimazoleA01AB18severe
  • CimetidineA02BA01severe
  • MetoclopramideA03FA01severe
  • DiphenhydraminA04AB05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/418fdb48-5cb2-46cf-b2d8-8a5c21d5e8ea
GET /v1/drugs/418fdb48-5cb2-46cf-b2d8-8a5c21d5e8ea?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablett, filmdrasjert",
  "source": "fest",
  "status": "A",
  "atc_name": "Brekspiprazol",
  "merkevare_id": "ID_86CB34FF-FF12-4A4F-A3F4-A87217259702",
  "name_form_strength": "Rxulti tab 2 mg",
  "prescription_group": "C"
}

See everything about brexpiprazole.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.